Our lawyers are investigating Ozempic lawsuits for patients with NAION, gastroparesis or gastrointestinal conditions, including bowel obstruction or cyclic vomiting syndrome.

Ozempic is the popular brand name for semaglutide, a prescription drug approved for the treatment of type 2 diabetes. As we all know, Ozempic is also commonly used as a weight management drug. Recent scientific studies have shown that taking Ozempic, particularly at higher doses, can cause gastroparesis.

Until recently, the warning label for Ozempic did not correctly notify patients or doctors about the risk of these injuries. Anyone who suffered injuries after taking Ozempic may be able to get financial compensation for their injuries by filing a product liability lawsuit.

Lawsuits involving Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro are consolidated in an MDL class action lawsuit. NAION lawsuits are growing but, as we explain in the updates below, vision loss cases are handled outside of the MDL. This page will provide the latest news and updates on the Ozempic litigation, as well as our predictions about the potential settlement value of these cases.

If you have an Ozempic lawsuit, call our lawyers today at 800-553-8082 or reach out to us online for a free consultation.

Ozempic Lawsuit Updates

Our Ozempic lawyers are dedicated to providing you with the latest updates and news on this litigation.  Come back frequently. Our attorneys update this page whenever there is a new development or an update

June 24, 2025 – Beyond Just NAION: Ozempic and Wegovy Linked to Increased Risk of Vision Loss

A new study in JAMA Ophthalmology has added another entry to the growing ledger of concerns about Ozempic and Wegovy, with yet more concerns involving the loss of vision.

Researchers from the University of Toronto found that patients taking semaglutide, the active ingredient in both drugs, were twice as likely to develop neovascular age-related macular degeneration (nAMD). This disease gradually destroys central vision and often leads to permanent impairment.

The study looked at nearly 140,000 patients with type 2 diabetes from 2020 to 2023. The risk was small in absolute terms, just over two in 1,000 for semaglutide users versus one in 1,000 for non-users. But the increase was real and statistically significant. Researchers controlled for other known risk factors, including kidney function, smoking, and the use of insulin and metformin.

What stands out is not just the result, but the biological plausibility: GLP-1 drugs like Ozempic alter vascular and inflammatory pathways. These are mechanisms directly implicated in macular degeneration. That ought to matter to doctors. It certainly should matter to patients.

Ozempic was not marketed as a weight loss miracle, but it became one. The public embraced it before science caught up. Now that evidence is emerging, first about stomach paralysis, now about vision, companies like Novo Nordisk will have to answer not just for what they disclosed, but for what they never bothered to investigate.

June 21, 2025 – New NAION Lawsuit

In a new lawsuit filed on Thursday in New Jersey Superior Court, a man from Woodbridge, New Jersey, alleges that his use of the weight-loss drug Wegovy caused him to suffer non-arteritic anterior ischemic optic neuropathy, resulting in permanent vision loss.

According to the complaint, the plaintiff used Wegovy, a GLP-1 receptor agonist, and subsequently developed NAION.

The lawsuit claims that the drug’s manufacturers failed to adequately warn consumers and healthcare providers about the risk of NAION. The plaintiff alleges that the company knew or should have known of the potential for Wegovy to cause optic nerve damage, yet continued to market the drug without proper safety disclosures.

He is seeking compensatory and punitive damages for his injuries, ongoing medical treatment, and diminished quality of life.

June 17, 2025 – NAION Claims Are Heating Up

Twenty-one New Jersey plaintiffs who say they suffered permanent vision loss after taking Ozempic or Wegovy are seeking to consolidate their lawsuits into a multicounty litigation against Novo Nordisk. They are asking New Jersey state courts to coordinate the growing number of cases involving a rare and irreversible eye condition called nonarteritic anterior ischemic optic neuropathy, or NAION. These plaintiffs argue that centralization would streamline discovery, reduce inconsistent rulings, and make the litigation more manageable as filings continue to increase, the same arguments that got us a gastroparesis MDL.

What is notable here is that the NAION claims are now generating more attention from lawyers than the earlier wave of gastroparesis lawsuits. While stomach paralysis cases helped launch the Ozempic litigation, the vision-loss allegations are getting a lot of buzz because the injuries are so significant.

Permanent blindness, especially when it develops suddenly and without prior warning, presents a particularly high-stakes form of injury that is more likely to motivate individual lawsuits, media coverage, and eventual jury trials.

As scientific studies continue to examine a possible causal link between GLP-1 receptor agonists and optic nerve damage,  these cases will continue to move to the center stage.

June 12, 2025 – MDL Case Count

There are currently 1,882 pending cases in the GLP-1 RA MDL (MDL 3094) in the Eastern District of Pennsylvania.  For a litigation that only began in early 2024, that is a solid number, and filings have been steady. The docket includes almost all gastroparesis claims.  There are an increasing number of vision loss lawsuits involving NAION, but this MDL does not cover those.

You will likely see a significant increase in Ozempic lawsuits after the judge rules on Daubert. Currently, many plaintiffs’ lawyers are waiting on the sidelines to see how the gastroparesis lawsuits unfold.

June 10, 2025 – NAION Warning

Momentum is building behind calls for the FDA to take action on Ozempic’s potential vision risks. Several ophthalmologists and public health advocates are now urging the agency to require a black box warning on semaglutide drugs, including Ozempic, Wegovy, and Rybelsus, in light of mounting evidence linking them to nonarteritic anterior ischemic optic neuropathy (NAION).

This comes after recent reports in JAMA Ophthalmology and a Danish registry study suggested a statistically significant association between semaglutide use and sudden vision loss events. The push for regulatory change is being amplified by attorneys involved in the New Jersey multicounty litigation effort, who argue that Novo Nordisk has long been aware of this potential risk but has failed to update its labeling accordingly.

A black box warning would represent a major shift. It would not only reshape physician prescribing behavior but could also open the door to new theories of liability for failure to warn. For plaintiffs’ lawyers, it would be a powerful piece of evidence showing that the dangers of NAION were both foreseeable and preventable.

Expect pressure to grow, especially as more independent case reports emerge and as media coverage draws attention to the life-altering nature of these injuries. This is not just a litigation story anymore—it is rapidly becoming a public health issue.

June 2, 2025 – Early Defense Strategy Emerges in Vision Loss Cases

Novo Nordisk is already telegraphing part of its defense strategy for the NAION lawsuits: blame the underlying health conditions. In several recent filings, the company has suggested that diabetes, hypertension, and high cholesterol, common among Ozempic users, are known risk factors for optic nerve damage and vision loss, and that any injury suffered by plaintiffs may be unrelated to semaglutide exposure.

This is a familiar pharmaceutical defense attorney playbook: frame the condition as multifactorial and shift the focus away from the drug’s role. But it is a risky strategy in front of a jury. Plaintiffs’ lawyers will argue that Novo Nordisk had an obligation to warn even if the drug only slightly increased the baseline risk, especially since patients with diabetes are already vulnerable to ocular damage and would be even more cautious if fully informed.

This line of defense also ignores the emerging scientific consensus that NAION events in semaglutide patients are occurring at a higher-than-expected rate. Some of the most severe injuries are showing up in people with no significant prior eye issues. If the litigation progresses to expert testimony and case-specific discovery, juries may not be sympathetic to a company that downplays catastrophic injuries as just a coincidence.

It is an early sign that the NAION litigation will not just mirror the gastroparesis MDL but could evolve into its own battleground, with distinct scientific questions, plaintiff demographics, and a higher potential for headline verdicts.

Ozempic

Ozempic (generically known as semaglutide) is a prescription medication that is used in the management of type 2 diabetes. Ozempic is part of a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1 is a hormone in the body that gets released in response to food intake and helps regulate blood sugar levels.

There is also evidence that Ozempic can induce weight loss in people with obesity, even those without diabetes. Ozempic is approved for the management of type-2 diabetes. Recently, however, doctors have prescribed Ozempic to treat obesity and weight management.

Ozempic is manufactured by the Dutch pharmaceutical company Novo Nordisk, which focuses primarily on the development and sale of diabetes drugs.

Ozempic was first developed by Novo Nordisk in 2012, and it was approved for use by the FDA and released on the U.S. market in December 2017. In 2021, a higher-dose version of Ozempic (sold under the brand name Wegovy) was approved by the FDA.

Ozempic (and other GLP-1 drugs) work by stimulating the production of insulin after meals. GLP-1 is a naturally occurring peptide in the body that helps control blood sugar levels. GLP-1 agonists mimic the effects of this peptide, making them useful in the treatment of type 2 diabetes.

So this drug helps to reduce blood sugar to normal levels. Ozempic also slows down the digestive process, which also helps to maintain normal glucose levels. Ozempic is administered as a once-weekly injection with a minimum dosage of 0.25 mg and a maximum dose of 1 mg.

Beyond its primary use for diabetes, the weight loss effects of Ozempic, observed during clinical trials, led to further exploration of the drug’s potential in this area. As a result, semaglutide has also been approved in higher doses under the name “Wegovy” for chronic weight management.

How does Ozempic work? It works great. The drug is sweeping the country and it is helping many patients. The question is, did the drug maker warn of all the risks so that a minority of patients did not unnecessarily suffer?

Gastroparesis Is Awful

Gastroparesis is essentially a stomach condition where the muscles don’t work as they should. Normally, strong muscle movements help move food along the digestive system. But if you have gastroparesis, this movement in your stomach is either too slow or doesn’t happen at all, making it hard for your stomach to empty food correctly.

This can mess up your digestion and lead to several problems, like feeling nauseous, throwing up (sometimes even food that hasn’t been digested), belly pain, bloating, getting severely dehydrated, feeling full quickly when eating, food not digesting and staying in the stomach, acid reflux, blood sugar levels going up and down, not feeling hungry, losing weight, not getting enough nutrients, and a drop in your quality of life.

The news gets worse: there is no known cure for gastroparesis.

So, if you are reading this and you are not a victim, imagine the hunger pangs that prompt you to nourish your body, only to be met with pain, nausea, and vomiting every time you try to eat.

This condition traps its sufferers in a relentless cycle of discomfort. With a stomach that refuses to cooperate, the basic human need to eat becomes a battleground. Every meal is a calculation, a risk, and often a regret. The physical symptoms are just the beginning; the psychological toll is equally devastating. The constant worry about when the next flare-up will occur, the anxiety of eating in public, and the stress of managing a diet that is both safe and nourishing can be overwhelming. It is miserable.

The pain and discomfort of gastroparesis are not fleeting, either. They linger and echo through every aspect of your life, casting a shadow over daily activities and social interactions. The chronic nature of the condition means that relief is often temporary and incomplete, leaving sufferers to navigate a maze of treatments and dietary adjustments in search of some semblance of normalcy.

Estimated Ozempic Lawsuit Settlement Amounts 

Estimating the potential settlement value of new product liability cases like this is almost impossible to do with any real accuracy. That is particularly true with the Ozempic gastroparesis lawsuits because they are very new. At this point, we don’t know how the scientific evidence behind these cases is going to hold up in court. That is a major variable in any defective drug case.

Still, victims want to know how much the Ozempic lawsuit is going to pay out? So what our lawyers can do, however, is provide an educated guess as to the possible settlement compensation payout range of Ozempic cases based on various assumptions about the causation evidence. Based on these significant assumptions, our attorneys believe that a successful Ozempic lawsuit could have a settlement value range of $400,000 to $700,000. This is the settlement value estimate for the “top tier” Ozempic cases, which would be those in which the plaintiff suffered severe gastroparesis or death.

In our April 5, 2024 update above, our attorneys talk about the type of cases we are seeing in this litigation. Some of them involve injuries that resolve quickly. You will not see settlement payouts anywhere near that number for those types of lawsuits. However, serious, permanent injury cases may yield significant value.

Practical Reasons That May Drive an Ozempic Settlement

The financial dynamics of the pharmaceutical market suggest significant potential payouts in the Ozempic-related litigation. These defendants are getting ridiculous profits from Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro. These companies are in a position to handle extensive settlement costs without crippling their financial standing.

Drug companies typically like to fight and drag out litigation as long as possible.  They also do not care as much as you would think about besmirching the name of the company with adverse publicity of big verdicts against them. But this is different – they are worried about the drug’s reputation and their ability to sell more of it.

It is the profits these drugs are bringing in that may change the calculus.  It may make it more likely that these companies will prefer settling claims out of court more quickly to protect their profits and avoid the public relations disaster of a verdict and the additional scrutiny that adverse verdicts on these drugs could bring.

The thinking is that these defendants might opt to offer substantial settlement payouts to quickly resolve the litigation and mitigate any negative publicity that could arise during a trial. Such a strategy not only helps maintain the brand’s market position but also potentially avoids the exposure of additional harmful evidence that could lead to even higher compensation claims or punitive damages.

So the expectation hope is that defendants will issue significant compensation to claimants sooner rather than later to circumvent the reputational damage and financial unpredictability associated with jury verdicts.

Weight Loss Lawsuits May Have Higher Values than for Diabetes

On September 28, 2023, the FDA added a new warning to the Ozempic label about the potential for increased risk of ileus, a blockage that keeps food or liquid from passing through the colon.

The new warning on the Ozempic label states that:

Ileus: Ileus is a serious but rare side effect that has been reported in patients taking Ozempic. Ileus can cause abdominal pain, nausea, vomiting, and constipation. If you experience any of these symptoms, contact your healthcare provider immediately.

The FDA also recommends that healthcare providers monitor patients taking Ozempic for signs and symptoms of ileus, and that they consider discontinuing Ozempic if ileus is suspected.

The point being underscored here is that we have a drug on the market, but the risks of the drug are far from nailed down.

The Focus of Every Ozempic Lawsuit Is the Failure to Warn

Every Ozempic lawsuit asserts the key claim in this litigation:  Novo Nordisk, the maker of Ozempic, failed to provide adequate warnings about the risk of developing gastroparesis, a condition characterized by delayed stomach emptying, as a side effect of the drug.

While the Ozempic label mentions common adverse reactions like nausea, vomiting, diarrhea, abdominal pain, and constipation, it does not link these symptoms to gastroparesis, nor does it include them in the “Warnings and Precautions” section. The label does mention delayed gastric emptying in the context of drug interactions. It describes a minor delay in gastric emptying as part of the drug’s mechanism. Still, it does not explicitly state gastroparesis as a risk or potential chronic condition resulting from Ozempic use.

Victims’ Ozempic lawyers argue that Novo Nordisk was aware or should have been aware of the potential link between Ozempic and gastroparesis, based on clinical studies, case reports, and medical literature. That is the core of these lawsuits. The company failed to provide adequate warnings about this risk, which allegedly led to a lack of awareness in the medical community and potentially affected prescribing decisions.

You also have to remember that we are not just talking about Ozempic in terms of clues to the risk. Ozempic is a  GLP-1 receptor agonist (GLP-1RA). The risk of gastroparesis is common across the GLP-1RA class, which includes medications like tirzepatide, exenatide, liraglutide, albiglutide, dulaglutide, and lixisenatide. Published literature on the association between gastroparesis and any GLP-1RA, not just Ozempic, should have alerted manufacturers to the need for warnings about this risk to patients and prescribing physicians.

Ozempic lawsuits contend that if the risks of gastroparesis had been adequately disclosed, it would have influenced the physician’s decision to prescribe Ozempic or to monitor for symptoms of gastroparesis more closely. Why not disclose the risk? There could be any number of reasons. But, like everything, it usually comes down to money. More warnings equal fewer sales, which equals less money. It is as simple as that.

Ozempic Class Action Lawsuit

In February 2024, the MDL panel certified an Ozempic class action lawsuit. A Multidistrict Litigation (MDL) class action can potentially speed up the settlement process in lawsuits like the Ozempic case in two important way that may lead to earlier Ozempic settlements:

Streamlined Proceedings: MDLs consolidate similar cases to streamline the legal process. By bringing numerous similar lawsuits under one court, MDLs help reduce duplicative discovery, avoid conflicting rulings in different courts, and increase the efficiency of the legal process. This consolidation can lead to quicker settlements because it creates pressure on the defendants to resolve many cases at once rather than dealing with each case individually over a prolonged period.

Higher Negotiation Leverage: In an MDL, the large number of cases consolidated together increases the plaintiffs’ negotiation leverage. This can encourage the defendant, in this case, Novo Nordisk, to settle to avoid the risk of facing a potentially large, cumulative judgment across many individual cases. Settlements in an MDL can offer compensation to claimants more quickly than individual lawsuits, which might take years to resolve. Ozempic settlement amounts are unlikely to be one-size-fits-all. If these claims are successful, Ozempic settlement payouts will vary depending on the severity of the side effects and the evidence supporting the plaintiffs’ claims.

Our lawyers sometimes refer to the Ozempic MDL (multidistrict litigation) as a class action lawsuit because that is what people call it (and, frankly, how they search it), but it is important to understand that these two legal mechanisms are distinct.

A class action lawsuit involves a group of plaintiffs who have suffered similar harm from the same defendant, and their cases are combined into a single lawsuit. This allows the group to be represented collectively by a member of the class, and any judgment or settlement applies to all class members. In a class action, the court must certify the class, establishing that the claims are sufficiently similar and that the representative parties will protect the interests of the class. You might see some classic Ozempic class actions filed in this litigation that include consumer claims for people who may not be injured.

On the other hand, an MDL consolidates individual Ozempic lawsuits with similar claims into a single court for pretrial proceedings, streamlining the process and making it more efficient. Each plaintiff in an MDL maintains their individual lawsuit, and their case is transferred back to its original court for trial if it does not settle during the MDL process. The primary goal of an MDL is to handle complex cases involving many plaintiffs and common factual issues more efficiently.

In the context of the Ozempic MDL, multiple individual cases related to the drug are consolidated for pretrial procedures. This allows for coordinated discovery and judicial efficiency but retains the individuality of each plaintiff’s claim. Unlike a class action, the outcomes in an MDL can vary for each plaintiff based on the specifics of their case.

Estimated Settlement Amounts for an Ozempic Lawsuit

Estimating the potential settlement value of new product liability cases like this is almost impossible to do with any real accuracy. That is particularly true with the Ozempic gastroparesis lawsuits because they are very new. At this point, we don’t know how the scientific evidence behind these cases is going to hold up in court. That is a major variable in any defective drug case.

Still, victims want to know how much the Ozempic lawsuit is going to pay out? So what our lawyers can do, however, is provide an educated guess as to the possible settlement compensation payout range of Ozempic cases based on various assumptions about the causation evidence. Based on these significant assumptions, our attorneys believe that a successful Ozempic lawsuit could have a settlement value range of $200,000 to $500,000. This is the settlement value estimate for the “top tier” Ozempic cases, which would be those in which the plaintiff suffered severe gastroparesis or death.

Some involve injuries that these drugs cause heal relatively quickly, and those cases will likely not see settlement payouts close to the larger figures. However, cases involving severe and permanent injuries may have significant value.

Practical Reasons That May Drive Settlement

The financial dynamics of the pharmaceutical market suggest significant potential payouts in the Ozempic-related litigation. These defendants are getting ridiculous profits from Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro. These companies  are in a position to handle extensive settlement costs without crippling their financial standing.

Drug companies typically like to fight and drag out litigation as long as possible.  They also do not care as much as you would think about besmirching the name of the company with adverse publicity of big verdicts against them. But this is different – they are worried about the drug’s reputation and their ability to sell more of it.

It is the profits these drugs are bringing in that may change the calculus.  It may make it more likely that these companies will prefer settling claims out of court more quickly to protect their profits and avoid the public relations disaster of a verdict and the additional scrutiny that adverse verdicts on these drugs could bring.

The thinking is that these defendants might opt to offer substantial settlement payouts to quickly resolve the litigation and mitigate any negative publicity that could arise during a trial. Such a strategy not only helps maintain the brand’s market position but also potentially avoids the exposure of additional harmful evidence that could lead to even higher compensation claims or punitive damages.

So the expectation hope is that defendants will issue significant compensation to claimants sooner rather than later to circumvent the reputational damage and financial unpredictability associated with jury verdicts.

Weight Loss Lawsuits May Have Higher Values than for Diabetes

Hiring an Ozempic Lawyer

If you have an Ozempic gastroparesis lawsuit, call our Ozempic lawsuit lawyers today at 800-553-8082 or reach out to us online for a free consultation.